Issoferrol Max (Deferasirox)

Issoferrol Max (deferasirox) is used to manage iron overload conditions that arise from chronic transfusion therapy.

• Chronic iron overload due to repeated blood transfusions: Reduces total body iron stores and prevents organ damage.
• Beta‑thalassemia major: Maintains safe iron levels to support regular transfusion regimens.
• Sickle cell disease: Controls transfusional iron accumulation to reduce complications.

• Deferasirox binds free iron with high affinity in the plasma and intracellularly, forming a stable 1:1 complex that is not readily re‑absorbed. The chelate is excreted predominantly via the feces, lowering circulating ferric iron and gradually depleting tissue iron deposits, thereby mitigating iron‑induced oxidative injury. Because the complex is highly lipophilic, it is absorbed into the gastrointestinal tract and eliminated without significant renal involvement, which helps preserve kidney function during long‑term therapy.

Deferasirox may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, often transient.
• Abdominal pain: cramp‑like discomfort.
• Rash: skin redness or itching.
• Elevated liver enzymes: mild increase in ALT/AST.
• Fatigue: general tiredness.

Serious or Rare Side Effects

• Acute kidney injury: sudden decline in renal function.
• Severe hepatic failure: marked elevation of liver enzymes and jaundice.
• Blood dyscrasias: neutropenia or thrombocytopenia.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy with Issoferrol Max, several safety considerations should be reviewed.

• Baseline assessment: Obtain liver function tests, renal function, and serum ferritin levels prior to treatment.
• Monitoring: Perform periodic liver and kidney labs to detect early toxicity.
• Pregnancy: Contraindicated in pregnancy (Category D); avoid use unless benefits outweigh risks.
• Pediatric use: Dose adjustments may be required for children; follow specialist guidance.
• Drug interactions: Review concomitant medications for potential major interactions.
• Store at ambient temperature: Keep below 25 °C in the original container, protect from moisture and direct sunlight.

Deferasirox can affect the pharmacokinetics of several co‑administered drugs; interactions are classified by clinical significance.

Major Interactions (Avoid)

• Cyclosporine: Increases deferasirox exposure, raising risk of renal toxicity.
• Rifampicin: Reduces deferasirox plasma levels, potentially decreasing efficacy.
• Antacids containing aluminum or magnesium: Decrease oral absorption of deferasirox.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): May enhance renal adverse effects.
• Vitamin C (high doses): Can increase iron‑chelator complex formation, altering iron balance.
• Statins: Potential for increased myopathy risk; monitor muscle symptoms.